Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: GEODON

Summary for Tradename: GEODON

Suppliers: see list10
patent expirations by year for

Pharmacology for Tradename: GEODON

Clinical Trials for: GEODON

A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Status: Completed Condition: Major Depressive Disorder

Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
Status: Completed Condition: Schizophrenia

Geodon for the Treatment of Refractory Social Anxiety Disorder
Status: Completed Condition: Social Anxiety Disorder

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions
Status: Completed Condition: Healthy

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression
Status: Completed Condition: Depression, Bipolar

Geodon in Weight Loss Study for Bipolar Disorders
Status: Completed Condition: Bipolar Disorder

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder
Status: Terminated Condition: Generalized Anxiety Disorder; Bipolar Disorder

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
Status: Completed Condition: Schizophrenia; Bipolar Disorder; Schizoaffective Disorder

Ziprasidone in Pediatric Bipolar Disorder
Status: Completed Condition: Bipolar Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
ziprasidone hydrochloride
SUSPENSION;ORAL021483Mar 29, 2006RXYes6,150,366<disabled>Y<disabled>
Pfizer Inc
ziprasidone hydrochloride
SUSPENSION;ORAL021483Mar 29, 2006RXYes6,245,766<disabled><disabled>
Pfizer Inc
ziprasidone hydrochloride
SUSPENSION;ORAL021483Mar 29, 2006RXYes7,175,855<disabled>Y<disabled>
ziprasidone hydrochloride
CAPSULE;ORAL020825Feb 5, 2001RXNo6,150,366<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: GEODON

Drugname Dosage Strength RLD Submissiondate
ziprasidone hydrochlorideCapsules20 mg, 40 mg, 60 mg and 80 mgGeodon2/7/2005

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology